MB076

MB076 is a novel heterocyclic triazole with improved plasma stability. MB076 inhibits seven different Class C Acinetobacter-derived cephalosporinases (ADCs) β-lactamase variants with Ki values [1].

Product Specifications

CAS Number

[2832966-95-5]

UNSPSC

12352203

Target

Antibiotic; Bacterial

Type

ADC Related

Related Pathways

Anti-infection

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/mb076.html

Solubility

10 mM in DMSO

Smiles

NC1=NN=C(SCC(N[C@H](B(O)O)CN2C=C(C(O)=O)N=N2)=O)S1

Molecular Formula

C9H12BN7O5S2

Molecular Weight

373.18

References & Citations

[1]Rachel A. Powers, et al. Synthesis of a Novel Boronic Acid Transition State Inhibitor, MB076: A Heterocyclic Triazole Effectively Inhibits Acinetobacter-Derived Cephalosporinase Variants with an Expanded-Substrate Spectrum. J Med Chem. 2023 Jul 13; 66 (13) : 8510–8525.